等待开盘 05-19 09:30:00 美东时间
+0.010
+0.32%
Original ResearchAbstract Title: Abstract #: Location: Date & Time:
05-13 20:06
Needham analyst Serge Belanger downgrades Esperion Therapeutics (NASDAQ:ESPR) from Buy to Hold.
05-05 03:05
今日重点评级关注:Benchmark:维持史密斯微软件"买入"评级,目标价从2美元升至2.5美元;Citizens:维持DBV Technologies"跑赢大市"评级,目标价从47美元升至55美元
05-04 16:04
Stocks traded mixed, with Dow down 0.1% but NASDAQ up 1.06%. Chevron reported mixed Q1 results. Esperion, Five9, Atlassian soared while Summit, Crescent, LendingTree fell.
05-02 03:39
US stocks traded higher, with the Nasdaq up 1%. Dow up 0.05%, Nasdaq up 1.13%, S&P 500 up 0.58%. Tech shares jumped 1.6%, energy stocks fell 1.5%.
05-02 02:15
Esperion Therapeutics shares rise premarket after agreeing to a ~$1.1B acquisition by ARCHIMED, offering $3.16 per share plus milestone payments.
05-01 20:27
Esperion Therapeutics (NASDAQ:ESPR) ("Esperion," or the "Company"), a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative cardiometabolic and rare/orphan disease therapies,
05-01 19:04
今日重点评级关注:Piper Sandler:维持Allogene疗法"超配"评级,目标价从7美元升至8美元;B. Riley证券:维持Oncology Institute"买入"评级,目标价从6美元升至8美元
03-16 18:19
Top Wall Street analysts changed outlook on top names: Adobe cut to $280, ServiceTitan to $100, KinderCare cut to $1.5, Nio upgraded to $6.8, Esperion raised to $5, Flagstar raised to $16, Nerdwallet cut to $9, Erasca raised.
03-13 20:09
Citizens analyst Jason N. Butler maintains Esperion Therapeutics (NASDAQ:ESPR) with a Market Outperform and raises the price target from $4 to $5.
03-13 18:36